Isabell M. Meier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Isabell M. Meier has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Marie Eikemo
Department of Psychology, University of Oslo, Oslo, Norway
10 shared publications - Martin Trøstheim
Surgical Department, Kongsberg Hospital, Vestre Viken Hospital Trust, Kongsberg, Norway
9 shared publications - Siri Leknes
Department of Psychology, University of Oslo, Oslo, Norway
9 shared publications - Guro Engvig Løseth
Department of Psychology, University of Oslo, Oslo, Norway
7 shared publications Jack van Honk
Department of Experimental Psychology Utrecht University Utrecht The Netherlands
6 shared publications- Peter A. Bos
Institute of Education and Child Studies Leiden University Leiden The Netherlands
5 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (11) , 2493-2502
Minor role of endogenous opioids for acute pain regulation in humans: a systematic review and meta-analysis of placebo-controlled antagonist studies
Endogenous opioids are widely regarded as the body's natural painkillers, lending credibility to the status of opioid medications as the gold-standard analgesics. When and how much endogenous opioids downregulate pain in humans remains unclear. To determine whether and under which conditions pharmacological opioid receptor blockade increased pain in healthy volunteers, we conducted a systematic review and meta-analysis of double-blind, randomized, placebo-controlled studies administering centrally active opioid antagonists during peripheral pain testing. Literature searches were performed in Web of Science, Scopus, PubMed, and EMBASE between October 7, 2020, and June 10, 2025. Three-level random-effects meta-regressions estimated standardized mean differences (Hedges' g) in pain intensity, tolerance, unpleasantness, and threshold between antagonist and placebo conditions. In secondary analyses, to determine under which conditions pain would be higher during mu-opioid blockade, we assessed the potential moderating role of study characteristics including pain modality, location, duration, nondrug interventions, and sample sex distributions. Sixty-seven studies were included (N = 2706). Across all pain outcomes, mu-opioid blockade was associated with slightly higher pain compared with placebo (Hedges' g [95% CI] = 0.18 [0.11, 0.25]), an increase of 2.8 points on a 0 to 100 pain intensity scale. Evidence of reporting bias suggested that the effect size was slightly overestimated. Although residual heterogeneity was substantial (I 2 = 66%), study characteristics explained little or none of this variance. The most credible evidence of endogenous opioid pain regulation was found for the placebo hypoalgesia category. Overall, the slight increase in pain sensitivity during opioid blockade in healthy volunteers indicates a minor role of endogenous opioids in human pain regulation.
- 14 September 2026
- Published by Wolters Kluwer Health in Pain
- Vol. 167 (11) , 2493-2502
Open AccessMinor role of endogenous opioids for acute pain regulation in humans: a systematic review and meta-analysis of placebo-controlled antagonist studies
Endogenous opioids are widely regarded as the body's natural painkillers, lending credibility to the status of opioid medications as the gold-standard analgesics. When and how much endogenous opioids downregulate pain in humans remains unclear. To determine whether and under which conditions pharmacological opioid receptor blockade increased pain in healthy volunteers, we conducted a systematic review and meta-analysis of double-blind, randomized, placebo-controlled studies administering centrally active opioid antagonists during peripheral pain testing. Literature searches were performed in Web of Science, Scopus, PubMed, and EMBASE between October 7, 2020, and June 10, 2025. Three-level random-effects meta-regressions estimated standardized mean differences (Hedges' g) in pain intensity, tolerance, unpleasantness, and threshold between antagonist and placebo conditions. In secondary analyses, to determine under which conditions pain would be higher during mu-opioid blockade, we assessed the potential moderating role of study characteristics including pain modality, location, duration, nondrug interventions, and sample sex distributions. Sixty-seven studies were included (N = 2706). Across all pain outcomes, mu-opioid blockade was associated with slightly higher pain compared with placebo (Hedges' g [95% CI] = 0.18 [0.11, 0.25]), an increase of 2.8 points on a 0 to 100 pain intensity scale. Evidence of reporting bias suggested that the effect size was slightly overestimated. Although residual heterogeneity was substantial (I 2 = 66%), study characteristics explained little or none of this variance. The most credible evidence of endogenous opioid pain regulation was found for the placebo hypoalgesia category. Overall, the slight increase in pain sensitivity during opioid blockade in healthy volunteers indicates a minor role of endogenous opioids in human pain regulation.
- Open Access
- 1 July 2026
- Published by Center for Open Science in PsyArXiv
The Repeatable Social Stress Test (ReSST): a guide and validation of a novel paradigm to elicit repeatable stress responses in humans
Stress induction tasks have been widely used to understand human stress mechanisms, yet are limited for assessing repeated or extended stress events, especially within-subject changes. Here, we provide a guide for implementation of the Repeatable Social Stress Test (ReSST), accompanied by validation results in healthy volunteers. The ReSST is developed to induce repeated stress responses both within and across sessions in a hybrid format, consisting of adaptions of the Trier Social Stress Test (TSST) and the Iowa Singing Social Stress Test (I-SSST) and two novel, closely matched no-stress control conditions. Video recordings designed to remind participants of the social-evaluative component of the stress induction are used for repeating stress within sessions. The ReSST was validated in 66 healthy volunteers aged 19-58 who completed 4 sessions (2 stress, 2 control). Compared to controls, both stress induction conditions elicited comparable, robust increases in subjective stress, heart rate, and cortisol, as well as marked changes in affect. Sex differences emerged, with women exhibiting stronger subjective responses. Cortisol responses did not significantly differ by sex. Stress reminders successfully evoked subjective and physiological responses within sessions, demonstrating reliable stress reactivation beyond the initial induction. In sum, the ReSST provides researchers with a validated, repeatable tool for inducing robust stress responses within and across sessions, enabling study of recurring stress in experimental settings. To accompany our guide, we provide a detailed step-by-step protocol and materials’ overview shared on OSF. Finally, we reflect on our experiences designing and implementing the ReSST in the context of broader literature.
- 1 July 2026
- Published by Center for Open Science in PsyArXiv
Open AccessThe Repeatable Social Stress Test (ReSST): a guide and validation of a novel paradigm to elicit repeatable stress responses in humans
Stress induction tasks have been widely used to understand human stress mechanisms, yet are limited for assessing repeated or extended stress events, especially within-subject changes. Here, we provide a guide for implementation of the Repeatable Social Stress Test (ReSST), accompanied by validation results in healthy volunteers. The ReSST is developed to induce repeated stress responses both within and across sessions in a hybrid format, consisting of adaptions of the Trier Social Stress Test (TSST) and the Iowa Singing Social Stress Test (I-SSST) and two novel, closely matched no-stress control conditions. Video recordings designed to remind participants of the social-evaluative component of the stress induction are used for repeating stress within sessions. The ReSST was validated in 66 healthy volunteers aged 19-58 who completed 4 sessions (2 stress, 2 control). Compared to controls, both stress induction conditions elicited comparable, robust increases in subjective stress, heart rate, and cortisol, as well as marked changes in affect. Sex differences emerged, with women exhibiting stronger subjective responses. Cortisol responses did not significantly differ by sex. Stress reminders successfully evoked subjective and physiological responses within sessions, demonstrating reliable stress reactivation beyond the initial induction. In sum, the ReSST provides researchers with a validated, repeatable tool for inducing robust stress responses within and across sessions, enabling study of recurring stress in experimental settings. To accompany our guide, we provide a detailed step-by-step protocol and materials’ overview shared on OSF. Finally, we reflect on our experiences designing and implementing the ReSST in the context of broader literature.
- Open Access
- 1 May 2026
- Published by Center for Open Science in OSF Preprints
Effects of Psychosocial Stress on Opioid Self-Administration in Healthy Participants: A Randomized, Placebo-Controlled Crossover Trial
Preclinical, epidemiological, and clinical studies converge upon psychosocial stress as a key risk factor for opioid misuse. Opioids are nevertheless frequently administered under conditions of stress, such as trauma or surgery. Here, we tested the hypothesis that acute psychosocial stress would increase opioid self-administration in healthy men and women with limited prior opioid exposure. In this triple-blind, block-randomized, placebo- and state-induction controlled, four-way crossover trial, social stress or a neutral control state was induced in a laboratory setting (2021-2022) prior to administration of a sampling dose of oxycodone (3mg/70kg iv) or saline. The primary outcomes were amount of oxycodone self-administered in an effortful task and self-reported drug desire (stress versus control). Changes in mood ratings, heart rate, and cortisol were also determined. Of 85 randomized participants (N=20-22 to each of four sequences), data from 66 participants comprising 257 sessions were eligible for analysis. Oxycodone induced a drug high but did not improve mood ratings or relieve stress compared to placebo. Expected opioid side effects were reported but no serious adverse events occurred. Hierarchical ordinal Bayesian regression models showed that stress credibly increased oxycodone self-administration by 6 percentage points (95% CrI [1, 10], Pr > 0.99). Moreover, a robust sex difference (19 percentage points, 95% CrI [10, 28] Pr >0.99) reflected that this effect was driven by male participants. Stress-enhanced opioid self-administration was not observed in the women tested here, nor linked to positive drug effects or stress relief in men or women. The results are consistent with heightened risk for persistent opioid use after exposure to opioid analgesics during high psychosocial stress burden.
- 1 May 2026
- Published by Center for Open Science in OSF Preprints
Open AccessEffects of Psychosocial Stress on Opioid Self-Administration in Healthy Participants: A Randomized, Placebo-Controlled Crossover Trial
Preclinical, epidemiological, and clinical studies converge upon psychosocial stress as a key risk factor for opioid misuse. Opioids are nevertheless frequently administered under conditions of stress, such as trauma or surgery. Here, we tested the hypothesis that acute psychosocial stress would increase opioid self-administration in healthy men and women with limited prior opioid exposure. In this triple-blind, block-randomized, placebo- and state-induction controlled, four-way crossover trial, social stress or a neutral control state was induced in a laboratory setting (2021-2022) prior to administration of a sampling dose of oxycodone (3mg/70kg iv) or saline. The primary outcomes were amount of oxycodone self-administered in an effortful task and self-reported drug desire (stress versus control). Changes in mood ratings, heart rate, and cortisol were also determined. Of 85 randomized participants (N=20-22 to each of four sequences), data from 66 participants comprising 257 sessions were eligible for analysis. Oxycodone induced a drug high but did not improve mood ratings or relieve stress compared to placebo. Expected opioid side effects were reported but no serious adverse events occurred. Hierarchical ordinal Bayesian regression models showed that stress credibly increased oxycodone self-administration by 6 percentage points (95% CrI [1, 10], Pr > 0.99). Moreover, a robust sex difference (19 percentage points, 95% CrI [10, 28] Pr >0.99) reflected that this effect was driven by male participants. Stress-enhanced opioid self-administration was not observed in the women tested here, nor linked to positive drug effects or stress relief in men or women. The results are consistent with heightened risk for persistent opioid use after exposure to opioid analgesics during high psychosocial stress burden.
- Open Access
- 5 August 2025
- Published by Center for Open Science in OSF Preprints
Minor role of endogenous opioids for acute pain regulation in humans: a systematic review and meta-analysis of placebo-controlled antagonist studies
Importance: Endogenous opioids are widely regarded as the body’s natural painkillers, lending credibility to the status of opioid medications as the gold-standard analgesics. When and how much endogenous opioids down-regulate pain in humans remains unclear, however. Objective: To determine whether and under which conditions pharmacological opioid receptor blockade is associated with increased pain responses in healthy volunteers.Data Sources: We searched Web of Science, Scopus, PubMed and EMBASE between October 7, 2020 and June 10, 2025. Study selection: Double-blind, randomized, and placebo-controlled studies that used peripheral pain interventions and administered a centrally active opioid antagonist were included. Data Extraction and Synthesis: Data extraction and risk of bias were assessed independently by 5 reviewers. Individual study quality was rated on the Jadad scale, while Egger’s test and funnel plots were used to evaluate reporting bias. Three-level random-effects meta-regressions were used to estimate pain perception during mu-opioid blockade compared to placebo. The reporting of this study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIS-MA) guidelines.Main Outcomes and Measures: The primary outcomes were estimated standardized mean difference (Hedges’ g) in pain intensity, tolerance, unpleasantness and threshold between antagonist and placebo. In secondary analyses, to determine under which conditions pain would be higher during mu-opioid blockade, we assessed the potential moderating role of study characteristics including pain modality, location, duration, non-drug interventions, and sample sex distributions.Results: A total of 67 studies were included (N=2706). Across the four pain outcomes, pain was slightly higher during mu-opioid antagonism compared to placebo (Hedges’ g [95% CI]=0.18 [0.11, 0.25]), approximately 2.8 points on a 0-100 pain intensity scale. Due to indications of re-porting bias, the effect size was suggested to be slightly overestimated. There was substantial residual heterogeneity (I2=66%), but study characteristics explained little or none of this variance. The most credible evidence of endogenous opioid pain regulation was found for placebo hypoalgesia. Conclusion and Relevance: Overall, the slightly higher pain sensitivity during experimental pain in healthy humans during opioid blockade indicates a minor role of endogenous opioids in human pain regulation.
- 5 August 2025
- Published by Center for Open Science in OSF Preprints
Open AccessMinor role of endogenous opioids for acute pain regulation in humans: a systematic review and meta-analysis of placebo-controlled antagonist studies
Importance: Endogenous opioids are widely regarded as the body’s natural painkillers, lending credibility to the status of opioid medications as the gold-standard analgesics. When and how much endogenous opioids down-regulate pain in humans remains unclear, however. Objective: To determine whether and under which conditions pharmacological opioid receptor blockade is associated with increased pain responses in healthy volunteers.Data Sources: We searched Web of Science, Scopus, PubMed and EMBASE between October 7, 2020 and June 10, 2025. Study selection: Double-blind, randomized, and placebo-controlled studies that used peripheral pain interventions and administered a centrally active opioid antagonist were included. Data Extraction and Synthesis: Data extraction and risk of bias were assessed independently by 5 reviewers. Individual study quality was rated on the Jadad scale, while Egger’s test and funnel plots were used to evaluate reporting bias. Three-level random-effects meta-regressions were used to estimate pain perception during mu-opioid blockade compared to placebo. The reporting of this study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIS-MA) guidelines.Main Outcomes and Measures: The primary outcomes were estimated standardized mean difference (Hedges’ g) in pain intensity, tolerance, unpleasantness and threshold between antagonist and placebo. In secondary analyses, to determine under which conditions pain would be higher during mu-opioid blockade, we assessed the potential moderating role of study characteristics including pain modality, location, duration, non-drug interventions, and sample sex distributions.Results: A total of 67 studies were included (N=2706). Across the four pain outcomes, pain was slightly higher during mu-opioid antagonism compared to placebo (Hedges’ g [95% CI]=0.18 [0.11, 0.25]), approximately 2.8 points on a 0-100 pain intensity scale. Due to indications of re-porting bias, the effect size was suggested to be slightly overestimated. There was substantial residual heterogeneity (I2=66%), but study characteristics explained little or none of this variance. The most credible evidence of endogenous opioid pain regulation was found for placebo hypoalgesia. Conclusion and Relevance: Overall, the slightly higher pain sensitivity during experimental pain in healthy humans during opioid blockade indicates a minor role of endogenous opioids in human pain regulation.
- Open Access
- 21 July 2023
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 49 (4) , 265-271
Factors associated with use of opioid rescue medication after surgery
Background Opioid exposure after surgery increases risk of persistent opioid use. Here, we characterize at-home use of opioid rescue medication during 1–2 days after outpatient surgery (N=270) in a postoperative opioid-sparing context at a Norwegian hospital. Methods The postsurgical pain management plan included non-steroidal anti-inflammatory drugs and up to six pills of 5 mg oxycodone as rescue analgesics. In this observational study we assessed risk factors for taking rescue opioids after surgery, by comparing patients who did, with those who did not. Results Only 35% (N=228) of patients reported taking rescue opioids 1–2 days after discharge. Patients taking rescue opioids after surgery (opioid-takers) differed from non-takers by prevalence of preoperative chronic pain (>3 months; 74% vs 48%), higher pain severity and interference before and after surgery, reporting lower ability to cope with postsurgical pain, higher nervousness about the surgery, being younger, and having received more opioid analgesics in the recovery room. Exploratory predictive modeling identified opioid administration in the recovery room as the most important predictor of at-home rescue medication use. Follow-up after >4 months indicated low acute pain levels (mean±SD = 1.1±1.8), with only four patients (2%, N=217) reporting opioid analgesic use. Conclusion Factors related to at-home rescue medication use closely mirrored known risk factors for persistent opioid use after surgery, such as prior chronic pain, prior substance use, affective disturbances, and pain severity before surgery. These findings are potential targets in patient-centered care. Nevertheless, and reassuringly, findings are consistent with the idea that opioid-sparing postsurgical care can prevent large-scale chronic opioid use.
- 21 July 2023
- Published by BMJ in Regional Anesthesia & Pain Medicine
- Vol. 49 (4) , 265-271
Open AccessFactors associated with use of opioid rescue medication after surgery
Background Opioid exposure after surgery increases risk of persistent opioid use. Here, we characterize at-home use of opioid rescue medication during 1–2 days after outpatient surgery (N=270) in a postoperative opioid-sparing context at a Norwegian hospital. Methods The postsurgical pain management plan included non-steroidal anti-inflammatory drugs and up to six pills of 5 mg oxycodone as rescue analgesics. In this observational study we assessed risk factors for taking rescue opioids after surgery, by comparing patients who did, with those who did not. Results Only 35% (N=228) of patients reported taking rescue opioids 1–2 days after discharge. Patients taking rescue opioids after surgery (opioid-takers) differed from non-takers by prevalence of preoperative chronic pain (>3 months; 74% vs 48%), higher pain severity and interference before and after surgery, reporting lower ability to cope with postsurgical pain, higher nervousness about the surgery, being younger, and having received more opioid analgesics in the recovery room. Exploratory predictive modeling identified opioid administration in the recovery room as the most important predictor of at-home rescue medication use. Follow-up after >4 months indicated low acute pain levels (mean±SD = 1.1±1.8), with only four patients (2%, N=217) reporting opioid analgesic use. Conclusion Factors related to at-home rescue medication use closely mirrored known risk factors for persistent opioid use after surgery, such as prior chronic pain, prior substance use, affective disturbances, and pain severity before surgery. These findings are potential targets in patient-centered care. Nevertheless, and reassuringly, findings are consistent with the idea that opioid-sparing postsurgical care can prevent large-scale chronic opioid use.
- Open Access
- 28 June 2023
- Published by Wiley in Anaesthesia
- Vol. 78 (9) , 1102-1111
Opioid analgesic effects on subjective well‐being in the operating theatre*
Summary: Exposure to opioid analgesics due to surgery increases the risk of new persistent opioid use. A mechanistic hypothesis for opioids' abuse liability rests on the belief that, in addition to pain relief, acute opioid treatment improves well‐being (e.g. via euphoria) and relieves anxiety. However, opioids do not consistently improve mood in laboratory studies of healthy non‐opioid users. This observational study determined how two commonly used opioid analgesics affected patients' subjective well‐being in standard clinical practice. Day surgery patients rated how good and how anxious they felt before and after an open‐label infusion of remifentanil (n = 159) or oxycodone (n = 110) in the operating theatre before general anaesthesia. One minute after drug injection, patients reported feeling intoxicated (> 6/10 points). Anxiety was reduced after opioids, but this anxiolytic effect was modest (remifentanil Cohen's d = 0.21; oxycodone d = 0.31). There was moderate to strong evidence against a concurrent improvement in well‐being (Bayes factors > 6). After remifentanil, ratings of ‘feeling good’ were significantly reduced from pre‐drug ratings (d = 0.28). After oxycodone, one in three participants felt better than pre‐drug. Exploratory ordered logistic regressions revealed a link between previous opioid exposure and opioid effects on well‐being, as only 14 of the 80 opioid‐naïve patients reported feeling better after opioid injection. The odds of improved well‐being ratings after opioids were higher in patients with previous opioid exposure and highest in patients with > 2 weeks previous opioid use (adjusted OR = 4.4). These data suggest that opioid‐induced improvement of well‐being is infrequent in opioid‐naïve patients. We speculate that peri‐operative exposure could increase risk of persistent use by rendering subsequent positive opioid effects on well‐being more likely.
- 28 June 2023
- Published by Wiley in Anaesthesia
- Vol. 78 (9) , 1102-1111
Open AccessOpioid analgesic effects on subjective well‐being in the operating theatre*
Summary: Exposure to opioid analgesics due to surgery increases the risk of new persistent opioid use. A mechanistic hypothesis for opioids' abuse liability rests on the belief that, in addition to pain relief, acute opioid treatment improves well‐being (e.g. via euphoria) and relieves anxiety. However, opioids do not consistently improve mood in laboratory studies of healthy non‐opioid users. This observational study determined how two commonly used opioid analgesics affected patients' subjective well‐being in standard clinical practice. Day surgery patients rated how good and how anxious they felt before and after an open‐label infusion of remifentanil (n = 159) or oxycodone (n = 110) in the operating theatre before general anaesthesia. One minute after drug injection, patients reported feeling intoxicated (> 6/10 points). Anxiety was reduced after opioids, but this anxiolytic effect was modest (remifentanil Cohen's d = 0.21; oxycodone d = 0.31). There was moderate to strong evidence against a concurrent improvement in well‐being (Bayes factors > 6). After remifentanil, ratings of ‘feeling good’ were significantly reduced from pre‐drug ratings (d = 0.28). After oxycodone, one in three participants felt better than pre‐drug. Exploratory ordered logistic regressions revealed a link between previous opioid exposure and opioid effects on well‐being, as only 14 of the 80 opioid‐naïve patients reported feeling better after opioid injection. The odds of improved well‐being ratings after opioids were higher in patients with previous opioid exposure and highest in patients with > 2 weeks previous opioid use (adjusted OR = 4.4). These data suggest that opioid‐induced improvement of well‐being is infrequent in opioid‐naïve patients. We speculate that peri‐operative exposure could increase risk of persistent use by rendering subsequent positive opioid effects on well‐being more likely.
- Open Access
- 25 November 2022
- Published by Wiley in Developmental Psychobiology
- Vol. 65 (1)
Preliminary data on oxytocin modulation of neural reactivity in women to emotional stimuli of children depending on childhood emotional neglect
Sensitivity for rewarding cues and distress signals from children is fundamental to human caregiving and modulated by the neuropeptide oxytocin. In a functional magnetic resonance imaging study, we investigated whether oxytocin regulates neural responses to reward or distress cues form children. In a placebo‐controlled, within‐subject design, we measured neural responses to positive, negative, and neutral cues from children in 22 healthy female subjects who received oxytocin (24 IU) versus placebo. Further, based on current literature, we hypothesized that oxytocin effects are modulated by experiences of childhood trauma. The task elicited valence‐specific effects—positive images activated the ventromedial prefrontal cortex, left anterior cingulate cortex, and right putamen, and images of children in distress activated the bilateral amygdala, hippocampus, and right medial superior frontal cortex. The effects of oxytocin depended on subjective reports of childhood emotional neglect. Self‐reported neglect interacted with oxytocin administration in the amygdala, hippocampus, and prefrontal areas. In individuals with higher scores of emotional neglect, oxytocin increased neural reactivity of limbic structures to positive and neutral images. Our findings need replication in larger samples and can therefore be considered preliminary but are in line with the recent literature on the modulating effect of childhood adversity on the sensitivity to oxytocin administration.
- 25 November 2022
- Published by Wiley in Developmental Psychobiology
- Vol. 65 (1)
Open AccessPreliminary data on oxytocin modulation of neural reactivity in women to emotional stimuli of children depending on childhood emotional neglect
Sensitivity for rewarding cues and distress signals from children is fundamental to human caregiving and modulated by the neuropeptide oxytocin. In a functional magnetic resonance imaging study, we investigated whether oxytocin regulates neural responses to reward or distress cues form children. In a placebo‐controlled, within‐subject design, we measured neural responses to positive, negative, and neutral cues from children in 22 healthy female subjects who received oxytocin (24 IU) versus placebo. Further, based on current literature, we hypothesized that oxytocin effects are modulated by experiences of childhood trauma. The task elicited valence‐specific effects—positive images activated the ventromedial prefrontal cortex, left anterior cingulate cortex, and right putamen, and images of children in distress activated the bilateral amygdala, hippocampus, and right medial superior frontal cortex. The effects of oxytocin depended on subjective reports of childhood emotional neglect. Self‐reported neglect interacted with oxytocin administration in the amygdala, hippocampus, and prefrontal areas. In individuals with higher scores of emotional neglect, oxytocin increased neural reactivity of limbic structures to positive and neutral images. Our findings need replication in larger samples and can therefore be considered preliminary but are in line with the recent literature on the modulating effect of childhood adversity on the sensitivity to oxytocin administration.
- Open Access
- 13 September 2022
- Published by Center for Open Science in PsyArXiv
Factors associated with use of opioid rescue medication after surgery
Opioid exposure after surgery increases risk of persistent opioid use. Here, we characterize at-home use of opioid rescue medication during acute recovery after day surgery (N=270) in an opioid sparing context. The post-surgical pain management plan included non-steroidal anti-inflammatory drugs and up to 6 pills of 5mg oxycodone to be taken as needed. Thirty-two percent of patients reported having taken at least one dose of opioid analgesic 1-2 days after discharge. Opioid-takers differed from non-takers by prevalence of chronic pain (>3 months; 74% versus 48%), significantly higher pain and pain interference levels before and after surgery, received more opioid analgesics in the recovery room, and younger age. Logistic regressions confirmed a predictive role of these measures for rescue opioid medication use during acute recovery. Opioid-takers also had lower self-reported ability to cope with pain during acute recovery, and higher worry before surgery, but did not differ significantly on prior opioid or tobacco use.Long-term follow-up (4-30 months) data included self-reported opioid use, pain catastrophising and overall substance use from 143 patients (53%); no additional differences were identified from these materials. Acute pain levels were low at long term follow-up and only four patients (2%) reported using opioid analgesics.In conclusion, pre-operative chronic and acute pain, younger age and self-reported difficulty in coping with pain during recovery emerge as valuable predictors of opioid self-administration in the acute recovery phase and could be targets in patient centred care.
- 13 September 2022
- Published by Center for Open Science in PsyArXiv
Open AccessFactors associated with use of opioid rescue medication after surgery
Opioid exposure after surgery increases risk of persistent opioid use. Here, we characterize at-home use of opioid rescue medication during acute recovery after day surgery (N=270) in an opioid sparing context. The post-surgical pain management plan included non-steroidal anti-inflammatory drugs and up to 6 pills of 5mg oxycodone to be taken as needed. Thirty-two percent of patients reported having taken at least one dose of opioid analgesic 1-2 days after discharge. Opioid-takers differed from non-takers by prevalence of chronic pain (>3 months; 74% versus 48%), significantly higher pain and pain interference levels before and after surgery, received more opioid analgesics in the recovery room, and younger age. Logistic regressions confirmed a predictive role of these measures for rescue opioid medication use during acute recovery. Opioid-takers also had lower self-reported ability to cope with pain during acute recovery, and higher worry before surgery, but did not differ significantly on prior opioid or tobacco use.Long-term follow-up (4-30 months) data included self-reported opioid use, pain catastrophising and overall substance use from 143 patients (53%); no additional differences were identified from these materials. Acute pain levels were low at long term follow-up and only four patients (2%) reported using opioid analgesics.In conclusion, pre-operative chronic and acute pain, younger age and self-reported difficulty in coping with pain during recovery emerge as valuable predictors of opioid self-administration in the acute recovery phase and could be targets in patient centred care.
- Open Access
- 8 August 2022
- Published by Center for Open Science in PsyArXiv
Do opioid analgesics improve subjective well-being? A prospective observational study of acute opioid effects before surgery
Exposure to opioid analgesics due to surgery increases the risk of new persistent opioid use. A mechanistic hypothesis for opioids’ abuse liability rests on the belief that in addition to pain relief, acute opioid treatment improves mood, e.g. via euphoria and anxiety relief. However, opioids do not consistently improve mood in laboratory studies of healthy non-opioid users. Here, we determined how two commonly used opioid analgesics affected patients’ subjective well-being in standard clinical practice. Day surgery patients rated their mood before and after open-label infusion of remifentanil (N=159) or oxycodone (N=110) on the operating table before general anesthesia. One minute after drug injection, patients reported feeling intoxicated (>6/10 points). As hypothesized, anxiety was reduced after opioids; this anxiolytic effect was however modest (remifentanil Cohen’s d=0.21; oxycodone d=0.31). Unexpectedly, we found moderate to strong evidence against a concurrent improvement in positive affect (Bayes Factors >6.5). After remifentanil, ratings of ‘feeling good’ were even significantly reduced from pre-drug ratings (d=0.28). After oxycodone, only 1 in 3 participants felt better than pre-drug. Ordered logistic regressions revealed a link between prior drug exposure and opioid mood effects: while opioid-naïve patients were unlikely to feel better (21%) after opioids, the odds were >4 times higher given a history of prolonged opioid use (>2 weeks, adjusted OR=4.4). In sum, these ecologically valid data suggest that mood improvement by opioids in opioid-naïve patients is infrequent. Nevertheless, perioperative exposure could mechanistically increase risk of persistent use by elevating the likelihood of positive mood improvement during post-operative opioid treatment.
- 8 August 2022
- Published by Center for Open Science in PsyArXiv
Open AccessDo opioid analgesics improve subjective well-being? A prospective observational study of acute opioid effects before surgery
Exposure to opioid analgesics due to surgery increases the risk of new persistent opioid use. A mechanistic hypothesis for opioids’ abuse liability rests on the belief that in addition to pain relief, acute opioid treatment improves mood, e.g. via euphoria and anxiety relief. However, opioids do not consistently improve mood in laboratory studies of healthy non-opioid users. Here, we determined how two commonly used opioid analgesics affected patients’ subjective well-being in standard clinical practice. Day surgery patients rated their mood before and after open-label infusion of remifentanil (N=159) or oxycodone (N=110) on the operating table before general anesthesia. One minute after drug injection, patients reported feeling intoxicated (>6/10 points). As hypothesized, anxiety was reduced after opioids; this anxiolytic effect was however modest (remifentanil Cohen’s d=0.21; oxycodone d=0.31). Unexpectedly, we found moderate to strong evidence against a concurrent improvement in positive affect (Bayes Factors >6.5). After remifentanil, ratings of ‘feeling good’ were even significantly reduced from pre-drug ratings (d=0.28). After oxycodone, only 1 in 3 participants felt better than pre-drug. Ordered logistic regressions revealed a link between prior drug exposure and opioid mood effects: while opioid-naïve patients were unlikely to feel better (21%) after opioids, the odds were >4 times higher given a history of prolonged opioid use (>2 weeks, adjusted OR=4.4). In sum, these ecologically valid data suggest that mood improvement by opioids in opioid-naïve patients is infrequent. Nevertheless, perioperative exposure could mechanistically increase risk of persistent use by elevating the likelihood of positive mood improvement during post-operative opioid treatment.
- Open Access
- 22 April 2022
- Published by Center for Open Science in PsyArXiv
Stress recovery with social support: A dyadic stress and support task
How does social support bolster resilience? Here, we present a new dyadic paradigm to study causal mechanisms of acute and ecologically valid social support in the laboratory. The Dyadic Stress and Support Task (DSST) consists of a psychosocial stress phase and a recovery phase. During DSST stress, a pair of participants take turns to perform public speaking and mental arithmetic in front of a panel. Unable to see or touch each other, they witness each other’s performance and feedback. During DSST recovery, the pair either interact freely with each other for 5 minutes (social support condition) or interact separately with an experimenter (non-support condition). To establish the validity of the DSST, we tested 21 pairs of long-term close friends in a pilot study. Primary outcome measures were ratings of affective state and bodily arousal (VAS scales 0-100). Secondary outcome measures were heart rate and salivary cortisol. DSST stress successfully induced subjective Stress Activation, increased Negative Affect and decreased Positive Affect. We also observed increased heart rate and salivary cortisol. After DSST recovery, Stress Activation and Negative Affect ratings were reduced in both groups. Positive Affect was completely restored to pre-stress baseline levels in the Social support group, while remaining significantly lower in the Non-support group. The DSST successfully induced stress and negative affect and captured stress recovery in both groups. Free-form interaction with the friend enhanced recovery of affective state, supporting the validity of spontaneous interaction between friends as a model of social support.
- 22 April 2022
- Published by Center for Open Science in PsyArXiv
Open AccessStress recovery with social support: A dyadic stress and support task
How does social support bolster resilience? Here, we present a new dyadic paradigm to study causal mechanisms of acute and ecologically valid social support in the laboratory. The Dyadic Stress and Support Task (DSST) consists of a psychosocial stress phase and a recovery phase. During DSST stress, a pair of participants take turns to perform public speaking and mental arithmetic in front of a panel. Unable to see or touch each other, they witness each other’s performance and feedback. During DSST recovery, the pair either interact freely with each other for 5 minutes (social support condition) or interact separately with an experimenter (non-support condition). To establish the validity of the DSST, we tested 21 pairs of long-term close friends in a pilot study. Primary outcome measures were ratings of affective state and bodily arousal (VAS scales 0-100). Secondary outcome measures were heart rate and salivary cortisol. DSST stress successfully induced subjective Stress Activation, increased Negative Affect and decreased Positive Affect. We also observed increased heart rate and salivary cortisol. After DSST recovery, Stress Activation and Negative Affect ratings were reduced in both groups. Positive Affect was completely restored to pre-stress baseline levels in the Social support group, while remaining significantly lower in the Non-support group. The DSST successfully induced stress and negative affect and captured stress recovery in both groups. Free-form interaction with the friend enhanced recovery of affective state, supporting the validity of spontaneous interaction between friends as a model of social support.